Rajan L Gupta

US Patent:

20080026050, Jan 31, 2008

Filed:

Jun 29, 2007

Appl. No.:

11/771571

Inventors:

Rajan Gupta - Bridgewater NJ, US
Surendra Sangekar - Union NJ, US

International Classification:

A61K 9/48
A61K 31/44
A61P 9/00
A61K 31/535

US Classification:

424451000, 514235200, 514337000

Abstract:

Capsule formulations of a thrombin receptor antagonist for oral administration are disclosed. In some embodiments, the thrombin receptor antagonist is COMPOUND 1: or a pharmaceutically acceptable isomer, salt, or solvate thereof. The formulations include at least one excipient, such as a diluent, disintegrant and/or lubricant. Also disclosed are methods of treating acute coronary syndrome and peripheral arterial disease, and of effecting secondary prevention, by orally administering such capsule formulations.

US Patent:

20080031943, Feb 7, 2008

Filed:

Jun 29, 2007

Appl. No.:

11/771520

Inventors:

Rajan Gupta - Bridgewater NJ, US
Suliman Chawdry - South Plainfield NJ, US
Srinivas Duggirala - Raritan NJ, US

International Classification:

A61K 31/4433
A61K 9/20

US Classification:

424464000, 514337000

Abstract:

Immediate-release formulations for oral administration of a thrombin receptor antagonist are provided. Certain formulations of higher API loading demonstrate sufficient moisture uptake after storage at stressed conditions to retard dissolution. The formulations of the present invention incorporate either lower API loading or elevated disintegrant-to-API ratios, found necessary to achieve disintegration rates required for immediate-release performance.

US Patent:

20190030018, Jan 31, 2019

Filed:

Jun 29, 2018

Appl. No.:

16/024581

Inventors:

- Summit NJ, US
James Carmichael - Nottingham, GB
Soraya Carrancio - San Diego CA, US
Jinhong Fan - San Mateo CA, US
Rajan Gupta - Bridgewater NJ, US
Gang Lu - San Diego CA, US
Kyle MacBeth - San Francisco CA, US
Emily Pace - Orinda CA, US
Daniel Pierce - Belmont CA, US
Michael Pourdehnad - San Francisco CA, US
Yu Pu - East Hanover NJ, US
Peng Wang - Westfield NJ, US
Naijun Wu - Princeton NJ, US
Sheena Yao - San Francisco CA, US

International Classification:

A61K 31/454
A61K 47/40
A61K 9/00
A61K 45/06
A61K 31/436
A61K 9/19
A61P 35/02

Abstract:

Provided herein are formulations and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

US Patent:

20160166544, Jun 16, 2016

Filed:

Aug 25, 2014

Appl. No.:

14/906085

Inventors:

Vincent Brett Cooper - Cheshunt, GB
Kathryn Alanna Bradley - St. Albans, GB
Samuel Robert PYGALL - Hoddesdon, GB
Rajan GUPTA - Cary NC, US
Madison Paige Stanford - San Francisco CA, US
Lin XIE - Long Valley NJ, US
- Rahway NJ, US
- Hoddesdon Hertfordshire, GB

International Classification:

A61K 31/4162
A61K 9/20
A61K 47/12
A61K 9/00
A61K 47/26
A61K 47/38

Abstract:

The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.